Study aims to uncover hidden side effects of common adrenal cancer drug

NCT ID NCT00568139

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 400 people with adrenocortical carcinoma who are taking mitotane as their first treatment. The goal is to carefully record all side effects, including ones that are not well understood. By collecting this data, researchers hope to improve how side effects are managed in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mitotane

What this could lead to

If successful, this study could provide clearer information on mitotane's side effects, helping doctors manage treatment better.

What could go wrong

This is an observational study, not testing a new treatment. It only documents known side effects, so it won't improve outcomes directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma adrenal gland cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital

    Würzburg, 97080, Germany